Autolus Therapeutics (AUTL) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
16 Nov, 2026Strategic position and manufacturing
AUCATZYL is the approved obe-cel product for adult r/r B-ALL; pediatric ALL, lupus nephritis and progressive MS are development opportunities.
Manufacturing success rate exceeded 90%, with fast, reliable product delivery and no capacity limitations reported in the first launch year.
Manufacturing priorities include process and operating-model optimization, more automation, and a next-generation platform targeting step-changes in cost and capacity.
Commercial performance
Q3 2026 net product revenue was $41.2M, up 95% vs Q3 2025; 9M 2026 revenue was $113.1M, up 122% vs 9M 2025.
FY 2026 net product revenue is expected to meet or exceed $150M, the upper end of prior guidance; 90 U.S. authorized treatment centers were listed.
Q3 2026 gross margin was 57% and YTD margin was 44%; peak gross margin expectation is 65–70%, supported by higher volumes and cost efficiencies.
Growth drivers include demand at existing U.S. centers, new centers coming online, UK sales, and additional ROCCA real-world data expected in Dec 2026.
Clinical evidence and pipeline
In FELIX, overall remission was 77% across 127 patients; Grade ≥3 CRS was 2% and Grade ≥3 ICANS was 7%, with no high-grade events among patients with <5% blasts at lymphodepletion.
FELIX follow-up showed 46.0% overall survival probability at 24 months; median duration of response was 42.6 months at the last data cut, with more than half of patients in remission at 24 months.
ROCCA real-world data included 91 patients receiving both infusions and 84 evaluable at Day 28; reported safety included no high-grade CRS and 3% high-grade ICANS.
CATULUS pediatric Phase 1 data showed 95.5% ORR and 90.9% CR at median follow-up of 8.8 months; Phase 2 is enrolling, with data expected by end-2027.
CARSLYLE’s 50M-cell cohort achieved DORIS in 5/6 patients and complete renal response in 3/6; LUMINA Phase 2 is enrolling 30 severe, refractory LN patients, with data anticipated in 2028.
BOBCAT is a Phase 1 obe-cel study in progressive MS; preliminary data are targeted for Q1 2027 and full Phase 1 data for 2H 2027.
Latest events from Autolus Therapeutics
- AUCATZYL scales commercially as margin gains and new indications build the next growth drivers.AUTL
Jefferies Global Healthcare Conference - AUCATZYL revenue rose 95%, gross margin reached 57%, and FY2026 guidance is at least $150M.AUTL
Q3 2026 - IPO-funded cash supports expanding T-cell trials, but losses and clinical risks remain significant.AUTL
Q4 2018 - A £113.5m loss funded a growing T-cell pipeline, with COVID-19 clouding timelines.AUTL
Q4 2019 - Cash runway extended to May 2023 as clinical development drives continued losses.AUTL
Q4 2021 - Licensing growth and a £316.3m cash balance offset a wider loss, with funding needed beyond June 2024.AUTL
Q4 2022 - Obe-cel advanced toward a 2024 decision, backed by encouraging data and $600M in February proceeds.AUTL
Q4 2023 - Resale registration for 3.5M ADSs linked to a warrant, supporting T cell therapy expansion.AUTL
Registration filing - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026